Conbercept therapy for neovascular age-related macular degeneration under the treat-and-extend regimen
10.3980/j.issn.1672-5123.2026.5.03
- VernacularTitle:治疗-延长方案下康柏西普治疗新生血管性年龄相关性黄斑变性的疗效观察
- Author:
Linrui LI
1
;
Jun LI
1
;
Yun LYU
1
;
Mingyue ZHANG
1
;
Moxiu GU
1
Author Information
1. Department of Ophthalmology, Fushun People's Hospital, Fushun County 643200, Sichuan Province, China
- Publication Type:Journal Article
- Keywords:
treat-and-extend;
neovascular age-related macular degeneration;
conbercept;
best-corrected visual acuity;
central macular thickness
- From:
International Eye Science
2026;26(5):738-745
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To assess the efficacy of intravitreal conbercept for treating neovascular age-related macular degeneration(nAMD)under a treat-and-extend(T & E)regimen.METHODS: A retrospective analysis was conducted on nAMD patients followed over a 2-year period(May 2020 to May 2022). All eyes received three monthly loading intravitreal injections of conbercept, followed by a T& E regimen in which the injection interval was extended by 2 or 4 wk according to disease activity, up to a maximum of 16 wk. When disease activity recurred, the interval was shortened. Patients were divided into initial and non-initial treatment groups based on treatment history. Best-corrected visual acuity(BCVA), central macular thickness(CMT), injection frequency, and intervals between injections over the 24-month follow-up were compared.RESULTS:Totally 27 patients(15 males and 12 females, 33 eyes)were enrolled. In the initial treatment group(18 eyes, mean age 65.72±12.32 y), BCVA significantly improved at 1, 3, and 6 mo(P<0.05), and CMT significantly improved at 1 and 3 mo(P<0.05). In the non-initial treatment group(15 eyes, mean age 69.00±9.21 y), BCVA improved significantly at 3 mo(P<0.05), whereas CMT remained stable(P >0.05). Baseline CMT was similar between the groups(P>0.05). However, significant differences were observed at multiple post-injection time points(P<0.05). The total number of injections did not differ between the groups(P>0.05). Intervals between injections varied, with the majority at 4 and 3-4 mo in the initial and non-initial treatment groups, respectively.CONCLUSION:Initiating intravitreal conbercept therapy under a T & E regimen results in superior visual and anatomical outcomes compared with non-initial treatment.
